SELLAS Life Sciences
45 hedge funds and large institutions have $15.5M invested in SELLAS Life Sciences in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 3 reducing their positions, and 4 closing their positions.
8,228% more call options, than puts
Call options by funds: $3.33M | Put options by funds: $40K
500% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 3
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
139% more capital invested
Capital invested by funds: $6.47M → $15.5M (+$8.99M)
45% more funds holding
Funds holding: 31 → 45 (+14)
6.92% more ownership
Funds ownership: 8.84% → 15.75% (+6.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$7.58M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$818K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$649K |
| 4 |
BlackRock
New York
|
+$112K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$161K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$77.9K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$55.6K |
| 4 |
Goldman Sachs
New York
|
-$16.3K |
| 5 |
RS
R Squared
Central,
Hong Kong
|
-$2.29K |
SLS Hedge Fund Activity: Q1 2025 in Review
45 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q1 2025, worth a combined $15.5M — up 139% from $6.47M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SLS positions and 4 closed out — a net gain of 14 holders — while 18 added to existing stakes and 3 trimmed.
The largest buyer was Anson Funds Management, adding an estimated $7.58M. The largest seller was Citadel Advisors, cutting an estimated $161K.
- 45 institutional investors held SELLAS Life Sciences (SLS) as of Q1 2025, up from 31 in Q4 2024.
- Funds reported $15.5M of SELLAS Life Sciences stock for Q1 2025, up 139% quarter-over-quarter.
- 18 funds opened new SELLAS Life Sciences positions in Q1 2025 and 4 closed out, a net change of +14 holders.
- The largest SELLAS Life Sciences buyer in Q1 2025 was Anson Funds Management, an estimated $7.58M added.
- The largest SELLAS Life Sciences seller in Q1 2025 was Citadel Advisors, an estimated $161K sold.
Based on aggregated 13F filings for Q1 2025.